- Home
- OZ vs LUNG Comparison
OZ vs LUNG Comparison
Compare OZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- LUNG
- Stock Information
- Founded
- OZ 2020
- LUNG 1995
- Country
- OZ United States
- LUNG United States
- Employees
- OZ N/A
- LUNG N/A
- Industry
- OZ
- LUNG Industrial Specialties
- Sector
- OZ
- LUNG Health Care
- Exchange
- OZ Nasdaq
- LUNG Nasdaq
- Market Cap
- OZ 254.2M
- LUNG 248.0M
- IPO Year
- OZ N/A
- LUNG 2020
- Fundamental
- Price
- OZ $63.55
- LUNG $6.45
- Analyst Decision
- OZ
- LUNG Strong Buy
- Analyst Count
- OZ 0
- LUNG 7
- Target Price
- OZ N/A
- LUNG $13.71
- AVG Volume (30 Days)
- OZ 3.6K
- LUNG 210.4K
- Earning Date
- OZ 01-01-0001
- LUNG 10-28-2024
- Dividend Yield
- OZ N/A
- LUNG N/A
- EPS Growth
- OZ N/A
- LUNG N/A
- EPS
- OZ N/A
- LUNG N/A
- Revenue
- OZ $1,700,000.00
- LUNG $76,583,000.00
- Revenue This Year
- OZ N/A
- LUNG $22.73
- Revenue Next Year
- OZ N/A
- LUNG $19.02
- P/E Ratio
- OZ N/A
- LUNG N/A
- Revenue Growth
- OZ N/A
- LUNG 26.26
- 52 Week Low
- OZ $42.75
- LUNG $5.46
- 52 Week High
- OZ $81.75
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- OZ 34.31
- LUNG 32.80
- Support Level
- OZ $69.01
- LUNG $6.56
- Resistance Level
- OZ $67.96
- LUNG $7.47
- Average True Range (ATR)
- OZ 0.92
- LUNG 0.38
- MACD
- OZ -0.94
- LUNG -0.22
- Stochastic Oscillator
- OZ 0.00
- LUNG 2.76
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.